Maternal

Maternal is a biotechnology company dedicated to developing first-in-class therapies for life-threatening conditions during pregnancy, with a primary focus on preeclampsia. The company's lead program is a small molecule therapeutic designed to address the underlying pathophysiology of preeclampsia, a leading cause of maternal and neonatal morbidity and mortality. By targeting the root causes of placental dysfunction, Maternal aims to extend pregnancy safely and improve outcomes for both mothers and infants. The company is currently in the pre-clinical stage, advancing its pipeline toward regulatory filings and clinical trials.